Agios Pharma (AGIO) Initiates AG-221 Phase 1/2 in Advanced Solid Tumors
Tweet Send to a Friend
Agios Pharma (NASDAQ: AGIO) announced the initiation of a Phase 1/2 multicenter study of AG-221 in patients with advanced solid ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
